{"podcast":{"title":"Raleigh News Today | 2 Min News | The Daily News Now!","slug":"raleigh-news-today-2-min-news-the-daily-news-now-7564076","podcast_index_feed_id":7564076,"rss_url":"https://feeds.fastcast.ai/the-raleigh-daily-news-now.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/podcasts/the-raleigh-daily-news-now.jpg","author":"The Daily News Now!","episode_count":2367,"summary":"Hosted by Corey with the Story, Raleigh News Today delivers daily coverage of everything happening in Raleigh with fast, focused updates on local news, government, business, public safety, weather, and the stories shaping the city. From economic growth to community developments, the show keeps you informed on what matters most across Raleigh. Each short episode highlights what matters most—including key updates, local trends, and stories shaping the city—produced by AI for speed, consistency, and clarity. Part of The Daily News Now network, Raleigh News Today is built for listeners who want reliable local news coverage in a quick, easy-to-digest format. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-07-27T08:18:44.566641+00:00","page_url":"https://stenobird.com/podcast/raleigh-news-today-2-min-news-the-daily-news-now-7564076"},"episode":{"title":"J&J Walks Away from Obesity Drug Rush","slug":"j-j-walks-away-from-obesity-drug-rush","published_at":"2026-06-24T16:50:08+00:00","page_url":"https://stenobird.com/podcast/raleigh-news-today-2-min-news-the-daily-news-now-7564076/j-j-walks-away-from-obesity-drug-rush","show_page_url":"https://stenobird.com/podcast/raleigh-news-today-2-min-news-the-daily-news-now-7564076","url":"https://api.fastcast.ai/audio/8dc8fb91-0e15-437b-9bde-48484263602c.mp3","audio_url":"https://api.fastcast.ai/audio/8dc8fb91-0e15-437b-9bde-48484263602c.mp3","summary":"Johnson & Johnson is boldly skipping the booming obesity drug race, opting instead to double down on cancer and brain disease research — a strategic pivot aimed at becoming the world’s top cancer drug company by 2030. CEO Joaquin Duato’s decision, backed by $3 billion in acquisitions, reflects a calculated move to avoid a crowded market dominated by rivals like Eli Lilly and Novo Nordisk. With blockbuster drugs losing steam and the obesity market projected to hit $95 billion, J&J sees oncology as a more defensible, high-impact growth path — one that could deliver $50 billion in sales by 2030. The gamble hinges on maintaining Darzalex’s momentum and successfully launching new therapies, but early signs are promising, with stock gains reflecting investor confidence. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/96f672602f4ff26a","meta_description":"Johnson & Johnson is boldly skipping the booming obesity drug race, opting instead to double down on cancer and brain disease research — a strategic pivot…","key_points":[],"chapters":[],"topics":[],"duration_seconds":154,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/raleigh-news-today-2-min-news-the-daily-news-now-7564076/episodes/j-j-walks-away-from-obesity-drug-rush/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/raleigh-news-today-2-min-news-the-daily-news-now-7564076/j-j-walks-away-from-obesity-drug-rush.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}